NeoGenomics, Inc. (NEO) exhibits mixed margin performance. The gross margin of 38.8% sits well below its ten‑year average of 42.5%, placing the company in the 18th percentile of its historical distribution and marking a year‑over‑year decline of 5.1%. Although the three‑year trend shows a modest 2.0% improvement, the recent back‑to‑back drop signals emerging pressure on cost structure or pricing power. Operating margin has turned slightly positive relative to its ten‑year average (-9.1% vs -8.8%) and is improving at a healthy pace (+4.9% YoY, +21.8% over three years), indicating better control of operating expenses. However, net margin remains deeply negative at -14.9%, below the zero threshold and lower than its ten‑year average of -6.6%, with a 2.9% YoY decline after prior improvement, triggering a critical alert.

NeoGenomics exhibits a mixed leverage profile. While its Debt-to-Equity ratio remains modest at 0.56x—only slightly above the 10‑year average of 0.49x and well within typical safety thresholds—the Net Debt/EBITDA metric has surged to an extreme 179.2x, far exceeding the historical average of 1.8x and placing the company at the 100th percentile of its ten‑year range. This divergence signals that earnings are insufficient to cover the ballooning net debt base, creating a pronounced solvency concern. Over the next 6‑18 months, the primary risk will be the company's ability to generate cash flow to service this debt, especially if interest coverage continues to deteriorate.

NeoGenomics exhibits a mixed cash generation profile. Operating cash flow is effectively zero in the current period, mirroring its ten‑year average, which signals that core operations are not producing surplus cash. Free cash flow is also reported as negative, confirming that cash outflows for capital expenditures and other investments exceed what the business generates internally. While liquidity metrics remain robust—current ratio at 4.26x, quick ratio at 3.94x, and cash ratio at 1.81x—these cushions are built on a balance sheet rather than ongoing cash generation, raising concerns if operating cash flow does not improve. The company’s short‑term liquidity is strong, comfortably above the typical safety thresholds of 1.5x for current and quick ratios and 0.8x for cash ratio. However, the absence of positive operating cash flow means that these ratios could deteriorate quickly should working capital needs rise or if financing sources tighten. The negative free cash flow alert underscores a critical need to monitor cash burn and the sustainability of investment outlays.

NeoGenomics exhibits significant concerns regarding the sustainability of its reported earnings. The income quality ratio (OCF/NI) is -0.05x, indicating that operating cash flow is not only far below net income but actually negative, well under the 0.8x safety threshold and suggesting that current earnings are largely accounting-driven rather than cash-backed. Compounding this, capital expenditures consume over five times the operating cash generated (CapEx/OCF = 516%), highlighting a severe cash‑flow mismatch that could force the company to rely on external financing or asset sales to fund growth.